NASDAQ:ADAP - Adaptimmune Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.98 -0.18 (-3.49 %)
(As of 12/17/2018 11:37 AM ET)
Previous Close$5.16
Today's Range$4.98 - $5.07
52-Week Range$4.82 - $14.63
Volume19,183 shs
Average Volume548,381 shs
Market Capitalization$487.19 million
P/E Ratio-6.28
Dividend YieldN/A
Beta2.02
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients. It is developing MAGE A-10 peptide that is in Phase I/II clinical trials for the treatment of urothelial, melanoma, and head and neck cancers, as well as non-small cell lung cancer (NSCLC); MAGE-A4 to treat urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, and gastric cancers; and AFP SPEAR T-cell therapeutic candidate that is in Phase I/II clinical trials for targeting a peptide associated with hepatocellular carcinoma. Adaptimmune Therapeutics plc has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with The University of Texas MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell therapy in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a co-development and co-commercialization agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.

Receive ADAP News and Ratings via Email

Sign-up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADAP
Previous Symbol
CUSIPN/A
Phone44-12-3543-0000

Debt

Debt-to-Equity RatioN/A
Current Ratio8.85
Quick Ratio8.85

Price-To-Earnings

Trailing P/E Ratio-6.28
Forward P/E Ratio-5.30
P/E GrowthN/A

Sales & Book Value

Annual Sales$37.83 million
Price / Sales12.43
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.17 per share
Price / Book2.29

Profitability

EPS (Most Recent Fiscal Year)($0.80)
Net Income$-70,130,000.00
Net Margins-139.57%
Return on Equity-41.63%
Return on Assets-33.15%

Miscellaneous

Employees371
Outstanding Shares94,420,000
Market Cap$487.19 million
OptionableOptionable

Adaptimmune Therapeutics (NASDAQ:ADAP) Frequently Asked Questions

What is Adaptimmune Therapeutics' stock symbol?

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

How were Adaptimmune Therapeutics' earnings last quarter?

Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) announced its earnings results on Tuesday, November, 6th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.09. The biotechnology company had revenue of $40.79 million for the quarter, compared to analyst estimates of $29.41 million. Adaptimmune Therapeutics had a negative net margin of 139.57% and a negative return on equity of 41.63%. View Adaptimmune Therapeutics' Earnings History.

When is Adaptimmune Therapeutics' next earnings date?

Adaptimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Adaptimmune Therapeutics.

What price target have analysts set for ADAP?

5 brokerages have issued 12 month price objectives for Adaptimmune Therapeutics' stock. Their forecasts range from $12.00 to $20.00. On average, they expect Adaptimmune Therapeutics' share price to reach $16.00 in the next twelve months. This suggests a possible upside of 218.7% from the stock's current price. View Analyst Price Targets for Adaptimmune Therapeutics.

What is the consensus analysts' recommendation for Adaptimmune Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adaptimmune Therapeutics.

What are Wall Street analysts saying about Adaptimmune Therapeutics stock?

Here are some recent quotes from research analysts about Adaptimmune Therapeutics stock:
  • 1. According to Zacks Investment Research, "Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. " (11/8/2018)
  • 2. Cowen Inc analysts commented, "We continue to expect positive data for the five-dose combination Phase 2 cohorts in 3Q18, and anticipate sustained serum uric acid suppression without ADAs. Selecta will present data for patients receiving 0.10 – 0.15 mg/kg SVP rapamycin combined with 0.2 mg/kg pegsiticase. The company plans to present multiple cohorts with up to n=20 patients per group. We expect data in 3Q18 to include a number of patients who have completed the full 5/6 dose combination regimen." (5/9/2018)
  • 3. Raymond James analysts commented, "Benjamin observed: Benjamin observed: We are maintaining our Outperform rating and increasing our price target to $20 (previously was $11) for ADAP given our increasing confidence in the company’s TCR franchise. Yesterday, the company reported 4Q17 financial results and provided an update on its TCR programs. Key takeaways include: 1) three partial responses (PRs) achieved by the NY- ESO TCR among four patients with myxoid/ round cell liposarcoma (MRCLS); 2) a slew of additional data readouts expected throughout 2018, including the first efficacy results from the MAGE-A10 and MAGE-A4 studies anticipated in 2H18; and 3) a cash runway through early 2020. With growing evidence from the NY-ESO TCR, multiple clinical data readouts expected from the wholly owned assets in 2018, a marquee partner like GlaxoSmithKline to move the NY-ESO program into pivotal studies, and a strong cash position of $188 million (pro forma), we continue to recommend shares of Adaptimmune to long-term, risk tolerant investors." " (4/22/2018)

Has Adaptimmune Therapeutics been receiving favorable news coverage?

News stories about ADAP stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Adaptimmune Therapeutics earned a news impact score of 1.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are some of Adaptimmune Therapeutics' key competitors?

Who are Adaptimmune Therapeutics' key executives?

Adaptimmune Therapeutics' management team includes the folowing people:
  • Mr. James Julian Noble, CEO & Director (Age 59)
  • Dr. Bent Jakobsen Ph.D., Scientific Co-Founder
  • Dr. Helen Katrina Tayton-Martin, Co-Founder & Chief Bus. Officer (Age 51)
  • Mr. Adrian Rawcliffe, Chief Financial Officer (Age 46)
  • Mr. William C. Bertrand Jr., Chief Operating Officer (Age 53)

When did Adaptimmune Therapeutics IPO?

(ADAP) raised $150 million in an initial public offering on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

Who are Adaptimmune Therapeutics' major shareholders?

Adaptimmune Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include NEA Management Company LLC (16.77%), Capital World Investors (7.19%), Baillie Gifford & Co. (3.62%), FMR LLC (2.38%), Renaissance Technologies LLC (1.09%) and Oracle Investment Management Inc. (0.95%). Company insiders that own Adaptimmune Therapeutics stock include Adrian Rawcliffe, Ali Behbahani, David M Mott, Enterprise Associates 14 New, Gwendolyn Knowlt Binder-Scholl, Orbimed Advisors Llc, Peter A Thompson and Ravi Viswanathan. View Institutional Ownership Trends for Adaptimmune Therapeutics.

Which major investors are selling Adaptimmune Therapeutics stock?

ADAP stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Tekla Capital Management LLC, Oracle Investment Management Inc., Capital World Investors, Renaissance Technologies LLC, Dorsey Wright & Associates, Foresite Capital Management II LLC and JPMorgan Chase & Co.. Company insiders that have sold Adaptimmune Therapeutics company stock in the last year include Adrian Rawcliffe, Gwendolyn Knowlt Binder-Scholl, Orbimed Advisors Llc and Peter A Thompson. View Insider Buying and Selling for Adaptimmune Therapeutics.

Which major investors are buying Adaptimmune Therapeutics stock?

ADAP stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Stanley Laman Group Ltd., Frontier Capital Management Co. LLC, Man Group plc, Capital International Investors, Baillie Gifford & Co., Point72 Asset Management L.P. and Bamco Inc. NY. Company insiders that have bought Adaptimmune Therapeutics stock in the last two years include Ali Behbahani, David M Mott, Enterprise Associates 14 New, Orbimed Advisors Llc and Ravi Viswanathan. View Insider Buying and Selling for Adaptimmune Therapeutics.

How do I buy shares of Adaptimmune Therapeutics?

Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adaptimmune Therapeutics' stock price today?

One share of ADAP stock can currently be purchased for approximately $5.02.

How big of a company is Adaptimmune Therapeutics?

Adaptimmune Therapeutics has a market capitalization of $487.19 million and generates $37.83 million in revenue each year. The biotechnology company earns $-70,130,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Adaptimmune Therapeutics employs 371 workers across the globe.

What is Adaptimmune Therapeutics' official website?

The official website for Adaptimmune Therapeutics is http://www.adaptimmune.com.

How can I contact Adaptimmune Therapeutics?

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 44-12-3543-0000 or via email at [email protected]


MarketBeat Community Rating for Adaptimmune Therapeutics (NASDAQ ADAP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  204 (Vote Outperform)
Underperform Votes:  191 (Vote Underperform)
Total Votes:  395
MarketBeat's community ratings are surveys of what our community members think about Adaptimmune Therapeutics and other stocks. Vote "Outperform" if you believe ADAP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADAP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel